<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01895712</url>
  </required_header>
  <id_info>
    <org_study_id>G1227</org_study_id>
    <nct_id>NCT01895712</nct_id>
  </id_info>
  <brief_title>BIOFLOW-III Israel Satellite Registry</brief_title>
  <official_title>Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Canada</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BIOTRONIK Israel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BIOTRONIK Israel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BIOTRONIK - SaFety and Performance Registry for a diabetic patient population with the .bimus&#xD;
      Eluting Orsiro Stent System Within daily clinical practice - III&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the majority of Coronary Artery Disease (CAD), treatment with Percutaneous Transluminal&#xD;
      Coronary Angioplasty (PTCA) provides high initial procedural success. However, the medium to&#xD;
      long-term complications range from rather immediate elastic recoil or vessel contraction to&#xD;
      longer processes like smooth muscle cell proliferation and excessive production of extra&#xD;
      cellular matrix, thrombus formation and atherosclerotic changes like restenosis or&#xD;
      angiographic re-narrowing. The reported incidence of restenosis after PTCA ranges from&#xD;
      30%-50%. Such rates of recurrence have serious economic consequences. Bare Metal Stents&#xD;
      (BMS), designed to address the limitations of PTCA, reduced the angiographic and clinical&#xD;
      restenosis rates in de novo lesions compared to PTCA alone and decreased the need for CABG.&#xD;
      BMS substantially reduced the incidence of abrupt artery closure, but restenosis still&#xD;
      occurred in about 20%-40% of cases, necessitating repeat procedures. The invention of Drug&#xD;
      Eluting Stents (DES) significantly improved on the principle of BMS by adding an&#xD;
      antiproliferative drug (directly immobilized on the stent surface or released from a polymer&#xD;
      matrix), which inhibits neointimal hyperplasia. The introduction of DES greatly reduced the&#xD;
      incidence of restenosis and resulted in a better safety profile as compared to BMS with&#xD;
      systemic drug administration. These advantages and a lower cost compared to surgical&#xD;
      interventions has made DES an attractive option to treat coronary artery disease.&#xD;
&#xD;
      An interesting group of analysis resulted to be diabetic patients. It has been concluded that&#xD;
      the incidence of both nonocclusive and occlusive restenosis is higher in diabetic subjects&#xD;
      after stenting as judged from comparison with historical control subjects. Results implicate&#xD;
      accelerated restenosis as both a consequence of diabetes and a cause for increased mortality&#xD;
      after PCI in diabetic patient.&#xD;
&#xD;
      Therefore this observational registry has been designed for the clinical evaluation of the&#xD;
      Orsiro LESS in diabetic subjects (Diabetic patients type 1 or 2) requiring coronary&#xD;
      revascularization with Drug Eluting Stents (DES). Results will contribute to the collection&#xD;
      of clinical evidence for the clinical performance and safety of the Orsiro Drug Eluting Stent&#xD;
      System in daily clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of cardiac death, any target vessel myocardial Infarction, coronary artery bypass graft and clinically driven target vessel revascularization)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of cardiac death, target vessel Q-wave or non-Q wave Myocardial Infarction (MI), emergent Coronary Artery Bypass Graft (CABG), clinically driven Target Lesion Revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total death</measure>
    <time_frame>12 months</time_frame>
    <description>Total death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12-month</time_frame>
    <description>Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death I death of unknown cause and all procedurerelated deaths, including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>12-month</time_frame>
    <description>Definite/probable-ARC define</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel myocardial infarction</measure>
    <time_frame>12-month</time_frame>
    <description>Myocardial infarction will be adjudicated according to the Joint ESC/ACCF/AHA/WHF Task Force universal definition of myocardial infarction12&#xD;
• 14and on the basis of the 2010 ARC extended historical definition of myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as any repeat revascularization of the target lesion</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Diabetes Mellitus Type 1 or 2</condition>
  <arm_group>
    <arm_group_label>Orsiro</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetic subjects (Diabetic patients type 1 or 2) requiring coronary revascularization with&#xD;
        Drug Eluting Stents (DES).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with diabetes mellitus Type 1 or 2&#xD;
&#xD;
          -  Stable coronary patients with moderate-severe symptomatic angina (CCS ≥II) and&#xD;
             evidence of myocardial ischemia per non- invasive test (nuclear or echo) or patients&#xD;
             with 'silent' myocardial ischemia and a large (e.g. &gt;10% of myocardium) territory of&#xD;
             myocardium in jeopardy (nuclear or echo)&#xD;
&#xD;
          -  Subject signed informed consent&#xD;
&#xD;
          -  Subject is geographically stable and willing to participate at all follow up&#xD;
             assessments&#xD;
&#xD;
          -  Subject is ≥ 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject did not sign informed consent&#xD;
&#xD;
          -  Left main disease&#xD;
&#xD;
          -  Complex bifurcations&#xD;
&#xD;
          -  Ostial lesions&#xD;
&#xD;
          -  Three vessel disease&#xD;
&#xD;
          -  Large visible thrombus&#xD;
&#xD;
          -  Heavy calcified lesions needing atherectomy or cutting balloon dilatation&#xD;
&#xD;
          -  Syntax Score ≥33&#xD;
&#xD;
          -  Active bleeding&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Chronic total Occlusion&#xD;
&#xD;
          -  Bleeding tendency obviate dual anti platelet (DAP) intake for one year&#xD;
&#xD;
          -  Hb&lt;11/Plts,100.000/WBC&lt;4000 or &gt;11.00&#xD;
&#xD;
          -  Pregnant or nursing subjects and those who plan pregnancy in the period up to 3 years&#xD;
             following index procedure. (Female subjects of child- bearing potential must have a&#xD;
             negative pregnancy test done within 28 days prior to the index procedure and&#xD;
             contraception must be used during participation in this trial)&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin,&#xD;
             antiplatelet medication specified for use in the study (clopidogrel and prasugrel and&#xD;
             ticlopidine, inclusive), sirolimus, poly (L-lactide) poly (DL-lactide), cobalt,&#xD;
             chromium, nickel, tungsten, acrylic and fluoro polymers or contrast sensitivity that&#xD;
             cannot be adequately pre-medicated. Planned surgery within 6 months of PCI unless dual&#xD;
             antiplatelet therapy will be maintained&#xD;
&#xD;
          -  Currently participating in another study and primary endpoint is not reached yet.&#xD;
&#xD;
          -  Other medical illness (e.g, cancer or congestive heart failure) or Known history of&#xD;
             substance abuse (alcohol, cocaine, heroin etc.) as per physician judgment that may&#xD;
             cause non-compliance with the protocol or confound the data interpretation or is&#xD;
             associated with a limited life expectancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ran Kornowski, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44410</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49104</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>July 5, 2013</study_first_submitted>
  <study_first_submitted_qc>July 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>International</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Observational registry</keyword>
  <keyword>Orsiro Drug Eluting Stents (DES)</keyword>
  <keyword>Stenting</keyword>
  <keyword>Treatment of Coronary Artery Disease</keyword>
  <keyword>Coronary revascularization</keyword>
  <keyword>Percutaneous Coronary Intervention (PCI)</keyword>
  <keyword>Diabetes Mellitus Type 1</keyword>
  <keyword>Diabetes Mellitus Type 2</keyword>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Angina</keyword>
  <keyword>Subgroups</keyword>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Small vessels</keyword>
  <keyword>Chronic Total Occlusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

